Luspatersept (Indonesian Wikipedia)
Analysis of information sources in references of the Wikipedia article "Luspatersept" in Indonesian language version.
refsWebsite
Global rank
Indonesian rank
1st place
1st place
3,984th place
4,575th place
5,225th place
low place
low place
low place
low place
low place
615th place
1,504th place
11th place
330th place
acceleronpharma.com (Global: low place; Indonesian: low place)
- "Luspatercept: Our Lead Product Candidate". Acceleron Pharma. Diarsipkan dari asli tanggal 5 March 2017. Diakses tanggal 22 May 2017.
businesswire.com (Global: 615th place; Indonesian: 1,504th place)
- "FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia" (Press release). Acceleron/Celgene. 18 May 2015. Diakses tanggal 22 May 2017 – via Business Wire.
canada.ca (Global: 1,712th place; Indonesian: 7,978th place)
- "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Diakses tanggal 25 March 2024.
celgene.com (Global: low place; Indonesian: low place)
ir.celgene.com
- "FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions". Celgene (Press release). 8 November 2019. Diarsipkan dari versi aslinya tanggal 13 November 2019. Diakses tanggal 13 November 2019.
clinicaltrials.gov (Global: 5,225th place; Indonesian: low place)
- "A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia". clinicaltrials.gov. 21 January 2022. Diakses tanggal 5 May 2022.
- "A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to the IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions". clinicaltrials.gov. 19 November 2021. Diakses tanggal 5 May 2022.
doi.org (Global: 2nd place; Indonesian: 4th place)
- Taher AT, Musallam KM, Cappellini MD (February 2021). "β-Thalassemias". The New England Journal of Medicine. 384 (8): 727–743. doi:10.1056/NEJMra2021838. PMID 33626255. S2CID 232049825.
- Piga A, Perrotta S, Gamberini MR, Voskaridou E, Melpignano A, Filosa A, et al. (March 2019). "Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia". Blood. 133 (12): 1279–1289. doi:10.1182/blood-2018-10-879247. PMC 6440118. PMID 30617198.
drugs.com (Global: 399th place; Indonesian: 480th place)
- "Reblozyl (luspatercept-aamt) FDA Approval History". Drugs.com. Diarsipkan dari versi aslinya tanggal 13 November 2019. Diakses tanggal 13 November 2019.
europa.eu (Global: 68th place; Indonesian: 182nd place)
ema.europa.eu
- "Reblozyl EPAR". European Medicines Agency (EMA). 28 April 2020. Diakses tanggal 26 September 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
ec.europa.eu
- "Reblozyl Product information". Union Register of medicinal products. Diakses tanggal 3 March 2023.
fda.gov (Global: 447th place; Indonesian: 792nd place)
- "New Drug Therapy Approvals 2019". U.S. Food and Drug Administration. 31 December 2019. Diakses tanggal 15 September 2020.
- "FDA approves first therapy to treat patients with rare blood disorder". U.S. Food and Drug Administration (FDA) (Press release). 8 November 2019. Diarsipkan dari versi aslinya tanggal 13 November 2019. Diakses tanggal 13 November 2019.
Artikel ini memuat teks dari sumber tersebut, yang berada dalam ranah publik. - "Drug Trials Snapshots: Reblozyl". U.S. Food and Drug Administration (FDA). 8 November 2019. Diakses tanggal 26 January 2020. Artikel ini memuat teks dari sumber tersebut, yang berada dalam ranah publik.
hres.ca (Global: low place; Indonesian: low place)
hpr-rps.hres.ca
- "Summary Basis of Decision (SBD) for Reblozyl". Health Canada. 23 October 2014. Diakses tanggal 29 May 2022.
nih.gov (Global: 4th place; Indonesian: 13th place)
pubmed.ncbi.nlm.nih.gov
- Taher AT, Musallam KM, Cappellini MD (February 2021). "β-Thalassemias". The New England Journal of Medicine. 384 (8): 727–743. doi:10.1056/NEJMra2021838. PMID 33626255. S2CID 232049825.
- Piga A, Perrotta S, Gamberini MR, Voskaridou E, Melpignano A, Filosa A, et al. (March 2019). "Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia". Blood. 133 (12): 1279–1289. doi:10.1182/blood-2018-10-879247. PMC 6440118. PMID 30617198.
dailymed.nlm.nih.gov
- "Reblozyl- luspatercept injection, powder, lyophilized, for solution". DailyMed. Diakses tanggal 17 September 2021.
ncit.nci.nih.gov
- "Luspatercept". NCI Thesaurus. National Cancer Institute.
ncbi.nlm.nih.gov
- Piga A, Perrotta S, Gamberini MR, Voskaridou E, Melpignano A, Filosa A, et al. (March 2019). "Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia". Blood. 133 (12): 1279–1289. doi:10.1182/blood-2018-10-879247. PMC 6440118. PMID 30617198.
semanticscholar.org (Global: 11th place; Indonesian: 330th place)
api.semanticscholar.org
tga.gov.au (Global: 3,984th place; Indonesian: 4,575th place)
- "Reblozyl". Therapeutic Goods Administration (TGA). 7 September 2021. Diakses tanggal 17 September 2021.
- "AusPAR: Luspatercept". Therapeutic Goods Administration (TGA). 28 April 2022. Diakses tanggal 28 April 2022.
web.archive.org (Global: 1st place; Indonesian: 1st place)
- "Luspatercept: Our Lead Product Candidate". Acceleron Pharma. Diarsipkan dari asli tanggal 5 March 2017. Diakses tanggal 22 May 2017.
- "FDA approves first therapy to treat patients with rare blood disorder". U.S. Food and Drug Administration (FDA) (Press release). 8 November 2019. Diarsipkan dari versi aslinya tanggal 13 November 2019. Diakses tanggal 13 November 2019. Artikel ini memuat teks dari sumber tersebut, yang berada dalam ranah publik.
- "Reblozyl (luspatercept-aamt) FDA Approval History". Drugs.com. Diarsipkan dari versi aslinya tanggal 13 November 2019. Diakses tanggal 13 November 2019.
- "FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions". Celgene (Press release). 8 November 2019. Diarsipkan dari versi aslinya tanggal 13 November 2019. Diakses tanggal 13 November 2019.